DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
MK-1775 is an investigational drug.
There have been 32 clinical trials for MK-1775. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck Sharp & Dohme Corp., and AstraZeneca.
Recent Clinical Trials for MK-1775
|Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers||National Cancer Institute (NCI)||Phase 1|
|Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study||National Cancer Institute (NCI)||Phase 1|
|Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|